Quell Therapeutics Initiates Phase 1/2 Trial for QEL-005 in Autoimmune Diseases
Quell Therapeutics is conducting Phase 1/2 trial of QEL-005, an autologous CAR-T therapy targeting CD19, in patients with dcSSc and D2TRA.
Company
Pharmaceutical intelligence for Quell Therapeutics with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.